Development of prophylactic vaccines against HIV-1

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 576kB
Preview	PDF (Authors’ Original Submitted Files for Images) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 139kB

Item Type:	Review
Title:	Development of prophylactic vaccines against HIV-1
Creators Name:	Schiffner, T., Sattentau, Q.J. and Dorrell, L.
Abstract:	The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.
Keywords:	Vaccine Design, Step Trial, Venezuelan Equine Encephalitis Virus, Modify Vaccinia Ankara, Elite Controller
Source:	Retrovirology
ISSN:	1742-4690
Publisher:	BioMed Central
Volume:	10
Page Range:	72
Date:	17 July 2013
Official Publication:	https://doi.org/10.1186/1742-4690-10-72
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year